The US cancer vaccines market represents a key component of the North American landscape, supported by the high prevalence of cancer, sophisticated healthcare infrastructure, strong pharmaceutical capabilities, and considerable spending on oncology research and development. According to The Insight Partners, the United States is a key market, with growth supported by the increasing prevalence of cancer and evolving industry dynamics.

According to The Insight Partners, the cancer vaccines market was estimated to be US$ 5.68 Bn in 2021 and US$ xx Bn in 2023. It is expected to reach US$ 16.86 Bn by 2031 and record a CAGR of 11.5% until 2031. The market's expansion is being driven by the increasing global incidence of cancer, growing investments in cancer vaccine research and development, advances in personalized cancer vaccines, and increasing emphasis on combination therapies. The report identifies an estimated total addressable market of approximately US$ 108.49 billion during 2024–2031, highlighting substantial commercial opportunities for companies operating in this field.

Download Sample PDF - https://www.theinsightpartners.com/sample/TIPRE00004595 

Cancer Vaccines Market Size, Share, Trends, Analysis, and Forecast

• Market Size: The global cancer vaccines market was valued at US$ 5.68 billion in 2021 and is projected to reach US$ 16.86 billion by 2031.
• Market Share: North America held a significant share of the global market in 2023, supported by cancer prevalence, high R&D expenditure, government grants, and advanced healthcare infrastructure.
• Growth Rate: The market is expected to register a CAGR of 11.5% during the forecast period.
• Market Trends: Personalized cancer vaccines, combination therapies, mRNA vaccine development, and increasing R&D investments are among the major trends shaping the industry.
• Market Drivers: The rising global incidence of cancer is a major growth driver. The report notes approximately 19.98 million cancer cases globally in 2022, with the number projected to reach 32.6 million by 2045.
• Technology Analysis: The market is segmented into dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, and viral vector cancer vaccines. Recombinant cancer vaccines held the largest share in 2023 and are anticipated to register the highest CAGR.
• Type Analysis: Preventive and therapeutic cancer vaccines constitute the major categories, with preventive cancer vaccines holding the largest share in 2023 and expected to register the highest CAGR.
• Indication Analysis: Cervical cancer, prostate cancer, and other indications are covered. Cervical cancer represented the leading indication segment in 2023 and is anticipated to maintain strong growth.
• End-User Analysis: The market is divided into pediatrics and adults, with the pediatrics segment holding the largest share in 2023 and projected to register the highest CAGR.
• 2034 Outlook: The supplied Insight Partners report provides a forecast through 2031, not 2034; therefore, a 2034 market size or CAGR should not be stated as an official Insight Partners forecast without additional data.

Market Drivers and Opportunities

The increasing burden of cancer worldwide remains one of the strongest factors supporting cancer vaccine development. Growing government and institutional support for vaccine research, increasing pharmaceutical R&D expenditure, and advances in immuno-oncology are encouraging companies to develop more targeted solutions. Personalized cancer vaccines and combination therapies are emerging as important areas of innovation, potentially enabling treatments tailored to individual tumor characteristics.

Another important opportunity lies in emerging economies. The Insight Partners highlights Asia-Pacific as the fastest-growing regional market, supported by increasing cancer prevalence, research activity, government support, and the growing number of biotechnology companies and startups.

However, the market faces challenges, including the relatively small number of commercially available cancer vaccines and high vaccine costs. These factors can limit accessibility and slow adoption, particularly in price-sensitive healthcare systems.

Regional Analysis

North America: North America held a significant market share in 2023. High cancer prevalence, substantial R&D spending, government funding, advanced healthcare infrastructure, and strong competition among market participants are expected to support continued growth.

Europe: Europe represents an important market supported by cancer research initiatives, established healthcare systems, and increasing interest in innovative immunotherapies.

Asia-Pacific: Asia-Pacific is identified as the fastest-growing region, driven by increasing cancer incidence, expanding research activities, government support, and growing biotechnology investment in countries such as China and Japan.

South and Central America: Increasing healthcare investment and the growing need for cancer prevention and treatment solutions are expected to create opportunities across the region.

Middle East and Africa: Improving healthcare infrastructure, greater awareness of cancer treatment options, and increasing investments in healthcare are expected to support gradual market development.

Cancer Vaccines Market Key Players

• CSL Limited
• ADURO BIOTECH INC.
• Astellas Pharma Inc.
• Merck & Co. Inc.
• Sanofi
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc.
• Dendreon
• AstraZeneca Plc.
• OSE Immunotherapeutics

These companies are profiled in the Insight Partners report, which evaluates industry participants and their competitive strategies and innovation developments.

Recent Developments

Cancer vaccine development is increasingly moving toward personalized and mRNA-based approaches. In December 2023, Oxford University Hospitals launched an mRNA cancer vaccine trial for patients with head and neck cancers. In February 2024, Moderna's mRNA-4359 cancer vaccine entered a trial at Imperial College Healthcare NHS Trust to evaluate its safety and potential efficacy in melanoma, lung cancer, and other solid tumors. Such developments demonstrate the industry's shift toward innovative vaccine platforms and personalized immuno-oncology solutions.

Get Premium Research Report Market Size and Report at:
https://www.theinsightpartners.com/buy/TIPRE00004595

About Us

The Insight Partners is an one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us

Ankit Mathur | The Insight Partners

E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish